The Sport Integrity Global Alliance renews the mandate of its founding CEO through 2030 as the organization continues its push for integrity in global sport ...

SIGA Technologies (SIGA) is back in focus after its 2025 earnings release, which showed lower annual revenue and net income, alongside ongoing contracts for TPOXX, pediatric development funding, and ...

Siga Technologies records an unusual rise in call option activity alongside steady institutional participation. Portfolio reallocations by major funds reflect evolving engagement with specialty ...

Generated TPOXX Product Revenues of $88 Million in 2025 Received $13 Million International Procurement Order for Oral TPOXX in January 2026 ...

SIGA Technologies (NasdaqGM:SIGA) has secured new multi-year international contracts for its antiviral TPOXX. The company recently received a $13 million procurement order from a country in the Asia ...

It’s déjà vu for Siga Technologies and its smallpox antiviral Tpoxx. At an interim analysis of a second mpox trial, the drug again missed the mark on a key measure of disease resolution. In patients ...

Siga Technologies has filed for FDA approval of an intravenous formulation of its smallpox treatment Tpoxx. The new formulation is designed to enable the treatment of patients who cannot swallow the ...

Senior execs at SIGA Technologies, controlled by Ron Perelman (pictured), dumped millions in shares after learning its $2.8B government contract was in jeopardy. Jeff Day Executives at a New York ...

Q4 2025 Management View CEO Diem Nguyen noted a continued focus on supporting governments globally in preparedness for biological threats, especially smallpox, with SIGA serving "as the leading ...